Cinna

Quick links to important sections

Cinna

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cinna

What is Cinna? Defining the Entity and Purpose

Cinna is a trade designation for a medication containing the active ingredient Cinnarizine (INN), a synthetic small molecule primarily supplied as an oral tablet for managing symptoms related to balance and motion. This compound is a piperazine derivative that targets vestibular function.

Property Description
Active ingredient Cinnarizine
Form Oral Tablet
Pharmacological class First-Generation Antihistamine and Calcium Channel Blocker
Common use Mitigating symptoms of vertigo and motion sickness
Origin Synthetic piperazine derivative

What Type of Medicine is Cinnarizine? Class and Dual Action

Cinnarizine is categorized with a dual pharmacological action, belonging to the First-Generation Antihistamine class and the Calcium Channel Blocker class. It is classified as an antivertigo preparation. While it shares the H1 receptor-blocking property of other antihistamines, its therapeutic profile is characterized by its activity as a calcium channel blocker, inhibiting the influx of calcium ions into specific sensory cells. This unique dual mechanism makes it a differentiated agent for vestibular issues, unlike general anti-nausea drugs.


What is Cinna Generally Used For? Core Therapeutic Purpose

The general therapeutic purpose of Cinnarizine is to stabilize the balance mechanisms of the body, specifically those in the inner ear. By acting as a labyrinthine suppressant, the medication calms the overactive sensory signals that frequently cause internal balance disturbances. This function is typically employed to provide relief during travel or to address sudden feelings of vertigo associated with inner ear disruption. Cinnarizine is used as an agent for vestibular disorders. Its primary benefit is to reduce the feelings of spinning, unsteadiness, and accompanying nausea that occur when the vestibular system is compromised.

What side effects are possible with Cinna?

Possible Side Effects and Safety Information

The safety profile of Cinna (Cinnarizine) is officially categorized by the frequency and physiological system affected, based on clinical data documented by regulatory authorities. The most frequently observed adverse reactions are generally related to the Nervous System and the Gastrointestinal Tract.

Frequency-Classified Adverse Reactions

Frequency Representative Effects
Common Somnolence (drowsiness), Nausea, Dry mouth
Uncommon Fatigue, Lethargy, Vomiting, Weight gain, Sweating

Clinically Significant Adverse Reactions and Safety Constraints

Certain rare but clinically significant effects have been documented in regulatory labels. These include the potential for Extrapyramidal Symptoms (movement disorders) and very rare cases of Cholestatic Jaundice (a liver condition) or Lupus-like skin reactions. These movement disorders are particularly associated with prolonged therapy and may be more likely to occur in older adults.

For patients with a pre-existing condition, the medication is contraindicated in cases of known hypersensitivity. Regulatory caution is also specifically noted for individuals with Parkinson's disease, as the medication may cause or exacerbate movement symptoms. Furthermore, the sedative effects of Cinnarizine may be potentiated if used concurrently with alcohol or other Central Nervous System (CNS) depressants.

Overdose and Emergency Response

Overdose with Cinnarizine may result in a constellation of symptoms primarily related to the central nervous system (CNS). Acute overdoses have been reported across a wide range of exposures, from 90 mg to over 2,250 mg. Documented clinical manifestations often include somnolence, progressing to stupor, and potentially coma. Other signs include vomiting, hypotonia (decreased muscle tone), and extrapyramidal symptoms. While clinical consequences were noted as not severe in most cases reported to regulators, deaths have been reported following both single and polydrug overdoses.

Immediate medical assistance is required if an overdose is suspected. It is advisable to contact a poison control centre to obtain the latest recommendations for management. Treatment is restricted to symptomatic and supportive care, as no specific antidote is known to exist for Cinnarizine. In situations involving a potentially toxic dose, the administration of activated charcoal may be considered, specifically within one hour of ingestion. A specific consideration for young children is the development of seizures or convulsions following overdose, necessitating observation in a health care facility for neurological complications.

Therapeutic Uses of Cinna

What Cinna Treats: Main Uses and Benefits

Management of Acute Symptomatic Discomfort

Cinna is commonly used to help manage acute symptomatic discomfort and is applied across domains where additional supportive management is needed. It is often applied for conditions presenting with disruptive symptom manifestations, such as nausea, dizziness, and related motion sickness. This use is relevant in clinical settings that involve acute or disruptive symptom patterns, where it supports the patient by easing distress and contributing to the overall symptom load. The medicine is commonly used in situations involving episodic changes.


Supporting Daily Comfort and Stability

Cinna is considered relevant for easing symptoms that interfere with daily functioning, particularly when groups of symptoms appear suddenly or fluctuate. It is used in situations involving certain distressing symptoms. The supportive relief provided assists with functional stability and contributes to improved comfort during symptomatic periods, which may help patients cope more steadily with symptom fluctuations.

“This medication plays a role in managing symptoms that create noticeable functional strain.”

Quick Fact: Symptomatic Support Cinna is relevant when symptoms become temporarily overwhelming and short-term symptomatic assistance is needed.

Eligibility and Restrictions for Use

Cinna's eligibility profile is strictly defined by regulatory authorities and specifies which populations may use the medicine and which are restricted or prohibited. The medicine is generally permitted for use by adults and children aged 5 years and over. Use is not recommended for children under this minimum age.

The drug is contraindicated and must not be used by individuals with a known hypersensitivity to cinnarizine or its components. It is also officially avoided in porphyria, an inherited blood condition.

Special consideration and caution are required for several populations. Patients with Parkinson's disease should only be given this medicine if the potential benefits are judged to outweigh the risk of aggravating their condition. The medicine must be used with care in individuals with renal or hepatic insufficiency. Older adults require particular caution due to increased susceptibility to certain side effects.

Furthermore, use is not recommended for women who are pregnant or breastfeeding due to a lack of established safety data for these physiological states. Individuals with conditions sensitive to anticholinergic effects, such as glaucoma or prostatic hypertrophy, must use this medicine with caution.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Cinna

Interaction scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Central Nervous System (CNS) Depressants
Specific interacting medicines (if explicitly listed) Tricyclic Antidepressants
Mechanistic basis of interactions (only if stated in label) Cinnarizine is extensively metabolized mainly via CYP2D6
Timing-based interaction rules (if applicable) Dermal Reactivity Indicators must be avoided within 4 days prior to testing
Population-specific interaction notes (if applicable) None explicitly documented as altering interaction severity.
Interaction-related restrictions Concurrent use of Alcohol may potentiate sedative effects

Interaction classifications (high-level)

Category Official Regulatory Statement
Interaction severity classification (as defined in official documents) Interactions are classified as those that may potentiate sedative effects (Pharmacodynamic interaction) and Diagnostic Interference (Procedural constraint)
Regulatory basis (EMA / FDA / etc.) Summaries of Product Characteristics (SmPC) from various national health authorities.
Interaction-context constraints (as defined in official documents) The antihistamine effect of Cinnarizine is the basis for the Dermal Reactivity Indicator constraint. Sedative potentiation is noted to occur, especially at the start of treatment

Resulting interaction structure

Official interaction statements:

  • Concurrent use of CNS Depressants or Tricyclic Antidepressants may potentiate the sedative effects of either Cinnarizine or the co-administered drug.
  • The use of Alcohol may potentiate the sedative effects of Cinnarizine, a constraint noted in regulatory documents.
  • Cinnarizine's antihistamine effect requires separation by 4 days prior to testing with Dermal Reactivity Indicators.
  • The drug is extensively metabolized mainly via the enzyme CYP2D6.

Connection to the overall interaction profile:

Regulatory documents define the product’s interaction profile based on an additive pharmacodynamic effect, resulting in sedation when combined with other CNS-active substances. An essential, non-therapeutic constraint is formalized as a mandatory four-day separation from diagnostic skin tests, a consequence of the drug's antihistamine properties. No drug-drug combinations are formally listed as contraindicated.

Mechanism of Action

Cinna, referencing Cinnamaldehyde or its derivatives, primarily modulates cellular processes through multiple molecular interactions. Its mechanism involves direct interaction with the thiol groups of cysteine residues on various cellular proteins, acting as a covalent modifier to alter protein function.

Intracellularly, Cinna influences redox homeostasis by modulating levels of reactive oxygen species (ROS). This action triggers mitochondrial dysfunction, leading to the release of cytochrome c and the subsequent intrinsic pathway of programmed cell death (apoptosis). This downstream cascade involves the activation of the caspase family of proteases, such as caspase-3 and caspase-9.

Cinna also functions as an inhibitor or modulator of several critical signaling pathways, including the NF-κB pathway and the MAPK family (e.g., JNK and p38). Modulation of these pathways affects the expression of pro- and anti-apoptotic proteins, such as the Bcl-2 family members. The overall system-level physiological consequence of this multi-target interaction profile is the selective initiation of programmed cell death in target cell populations and the broad modulation of cellular survival and inflammatory signaling.

Dosage and Administration Information

The administration of Cinna (Cinnarizine) is via the oral route. The medication follows distinct patterns for long-term maintenance and short-term prophylactic administration.


Administration Principles and Dosage

The standard regimen for balance disorders is generally 25 mg taken three times daily (TID) in divided doses. For the prevention of motion sickness, the initial dose is typically 25 mg taken well in advance of travel, with repeat doses permitted every 6 to 8 hours during the journey. The total amount administered in one day must not exceed the specified maximum daily dose of 225 mg. Dosage may be gradually adjusted over time for balance disorders.


Timing and Procedural Use

Cinna tablets are typically taken preferably after meals to support proper administration and may be ingested by swallowing whole, chewing, or sucking. If an intake is missed, the subsequent dose must maintain a minimum interval of eight hours; a double dose must not be taken. Specific guidance exists for certain patient groups; for instance, the dose for children aged 5 to 12 years receiving the medicine for motion sickness is half the adult dose. The duration of use is structured by the need: short-term for motion sickness prophylaxis, but potentially required for several months for inner ear conditions.

Recent Clinical Evidence

Clinical Research on Vestibular Vertigo

Research exploring Cinna in the context of vestibular vertigo—the sensation of spinning or unsteadiness caused by issues in the inner ear—has primarily utilized short-term, randomized controlled trials (RCTs) and meta-analyses that pooled data from these trials. These are studies where participants are randomly assigned to receive the medicine, a combination, or a placebo (an inactive pill). Researchers focused on how symptoms change over time in adults with various vertigo causes. The key outcomes monitored included patient-reported outcomes describing perceived discomfort, typically the Mean Vertigo Score (MVS), which is used in research examining symptom intensity or variability.

Evidence derived from meta-analyses: studies that combine and analyze results from multiple RCTs—involving a fixed-dose combination product that includes Cinnarizine alongside another agent studied for conditions characterized by fluctuating manifestations. These studies monitored short-term, episodic symptom patterns over periods generally lasting around four weeks. Older studies on Cinnarizine used alone, or as monotherapy, was also observed in some studies, but this research tends to be older and involves smaller populations.

Studies for Motion Sickness Prevention

Cinna was studied for motion sickness, which involves symptoms like nausea and dizziness caused by travel. Research on this indication mainly includes controlled clinical trials, many of which were conducted some time ago. These studies explored short-term symptom changes and research examined the medicine’s use in healthy adults before and during exposure to motion, such as sea travel. Research explored whether there were changes in outcomes related to physical discomfort, such as nausea and vomiting.

What Remains Uncertain in the Research Landscape

One of the clearest limitations is that the largest amount of contemporary evidence stems from studies focused on the fixed-dose combination product, and research has yet to explore whether Cinnarizine monotherapy findings may be similar in new, large-scale trials. Furthermore, follow-up durations were limited in many pivotal studies. Research exploring short-term symptom changes provides context, but research does not determine whether an individual will respond similarly regarding long-term maintenance of symptoms.

Key Studies & References

  1. Public Assessment Report National Procedure Cinnarizine 15mg Tablets cinnarizine PL 48836/0014 Osgen Pharmaceuticals Limited - MHRA (UK Regulatory Document)
  2. Public Assessment Report Mutual Recognition Procedure: Arlevert Tablets (Cinnarizine/Dimenhydrinate Combination)
  3. Australian Public Assessment Report for Cinnarizine / Dimenhydrinate - Therapeutic Goods Administration (TGA)

Frequently Asked Questions (FAQ)

Common questions about Cinna (FAQ)

Q: Is Cinna the same type of medicine as [similar drug name]?

A: Cinna is officially classified as having a dual pharmacological action. It acts as both a First-Generation Antihistamine and a Calcium Channel Blocker. This unique combination is noted in official product information to act as a labyrinthine suppressant to help stabilize balance mechanisms.

Q: Does Cinna always have to be taken at the same time every day?

A: Official dosing guidelines often describe the regimen for Cinna, frequently involving administration three times daily. Regulatory administration principles often suggest a minimum interval between doses, and maintaining a consistent time frame for administration helps adhere to the intended schedule.

Q: Can Cinna cause long-term side effects?

A: Official safety documents include warnings about the risk of certain effects occurring with prolonged therapy. Specifically, movement disorders known as Extrapyramidal Symptoms are associated with longer use and may be more likely to occur in older adults.

Q: Are there any common foods or drinks that interact with Cinna?

A: Regulatory documents mention two main points regarding intake. The medicine is instructed to be taken after meals to help reduce the chance of gastrointestinal irritation. It is also noted that drinking alcohol concurrently may increase the sedative effects of Cinna.

Q: Do older adults typically use Cinna differently than younger adults?

A: Official regulatory guidance requires that the medicine be used with particular caution in older adults. This is because this population is generally more susceptible to certain adverse effects, especially sedation and the movement disorders known as extrapyramidal symptoms.

Q: Is it normal to feel a change in appetite while taking Cinna?

A: According to the official list of adverse reactions, weight gain is noted as an uncommon side effect of Cinna. This effect may be related to changes in appetite during treatment.

Q: Can Cinna cause dizziness or affect driving?

A: Official product characteristics list Somnolence (drowsiness) as a common side effect of Cinna, particularly when starting treatment. Regulatory warnings indicate that due to this potential effect, activities requiring mental alertness, such as driving or operating machinery, should be avoided if affected by drowsiness.

Q: Has Cinna been studied in diverse patient populations?

A: Regulatory review documents indicate the medicine has been studied in patient groups with comorbidities like hepatic or renal insufficiency and includes warnings for use in individuals with Parkinson's disease. This provides context on the characteristics of the populations studied in research.

Q: Does Cinna affect sleep patterns?

A: Official product information lists Somnolence (drowsiness) as a common side effect, especially when a person first begins using the medicine. This is a recognized central nervous system effect that can influence a person’s wakefulness.

Q: What is the likelihood of a serious side effect from Cinna?

A: Regulatory documents categorize side effects by frequency, such as Common and Uncommon. More serious, clinically significant effects like Extrapyramidal Disorders are specifically noted in warnings and categorized by official bodies to communicate their low but recognized occurrence.

Q: Do you need a special diet when taking Cinna?

A: Official administration instructions state that the tablets should be taken after meals to help reduce the risk of stomach irritation. No specialized dietary restrictions, such as avoiding specific vitamins or food types, are mandated in the regulatory documents.

Q: What if I'm allergic to one of the inactive ingredients in Cinna?

A: The official product characteristics documents list all excipients (inactive ingredients) used in the medicine. Regulatory contraindications state that Cinna must not be used by individuals with a known hypersensitivity to the active substance or any of the listed components.

Q: How is Cinna thought to be eliminated from the body?

A: According to official pharmacokinetic information, Cinna is primarily eliminated after being metabolized by the liver. Approximately two thirds of the resultant metabolites are excreted in the faeces, with the remaining one third excreted in the urine.

Q: Does Cinna affect mood or mental clarity?

A: Official information indicates that the medicine is associated with somnolence, which can affect mental clarity. Regulatory warnings also advise caution in patients with a history of depression, as the medicine may cause symptoms like low mood in some individuals.

Q: How quickly does Cinna usually start to work?

A: According to pharmacokinetic data, the effect of the medicine can typically be observed within an hour after oral administration. The concentration of the active ingredient in the bloodstream usually reaches its peak 1 to 3 hours after a dose.

Q: Does Cinna interact with common over-the-counter pain relievers?

A: Regulatory information advises caution regarding the combined use of Cinna with central nervous system depressants. The sedative effects of Cinna may be potentiated (made stronger) by other medicines, which can include certain pain relievers.

Q: What happens if I stop taking Cinna suddenly?

A: Regulatory patient information states that stopping the medicine should be discussed with a healthcare professional. For those treating conditions like inner ear problems, discontinuing treatment abruptly may cause the original symptoms to return.

Q: Is Cinna a controlled substance?

A: In some jurisdictions, the medicine is classified by regulatory authorities as a Prescription-Only Medicine (POM) or a Pharmacy Medicine (P). Official documents do not classify Cinna as a strictly controlled substance in these areas.

Q: Is there a generic version of Cinna available?

A: Yes, the active ingredient in Cinna is Cinnarizine, and it is widely available. Regulatory product documents refer to the generic name, which is supplied under its non-proprietary name and in multiple branded and non-branded tablet forms internationally.

Q: Can Cinna be taken with herbal supplements?

A: Official guidance advises caution when considering the use of Cinna alongside herbal products or supplements. This is particularly true for products that may cause effects similar to Cinna, such as sleepiness, due to the potential for an additive sedative effect.

Q: Are headaches a common side effect of Cinna?

A: Headache is listed as a potential side effect in the official product characteristics provided by regulatory bodies. However, somnolence (drowsiness) and nausea are typically noted as the most common adverse reactions.

Q: Does Cinna interact with birth control pills?

A: Official patient information states that Cinna does not affect the efficacy of hormonal contraceptives, such as birth control pills. However, if the medicine causes vomiting, protection from the pill may be reduced.

Q: What is the shelf life of Cinna?

A: Official regulatory product characteristics define the approved shelf life for the medicine. For the tablet formulation, this is typically stated to be 3 years when stored according to the specified conditions.

Q: Is Cinna available in different strengths?

A: Yes, regulatory product information documents detail that the medicine is available in several tablet strengths. This includes tablets of 15 mg and 75 mg to align with differing dosing requirements.

Q: What is the legal classification of Cinna (prescription-only, etc.)?

A: The legal classification depends on the specific country's regulatory body. In many jurisdictions, the medicine is classified as a Prescription-Only Medicine (POM) or a Pharmacy Medicine (P), meaning it is not generally available for open-shelf purchase.

Q: What common supplements or vitamins might interact with Cinna?

A: Official guidance advises caution with herbal supplements, especially those that cause effects similar to Cinna, such as sleepiness. This warning is issued due to limited specific safety data when combining these products.

Q: What is the typical duration of effect for a dose of Cinna?

A: The therapeutic duration for a single dose is generally stated in official product information. The typical duration of the effect is said to last for 6 to 8 hours, supporting the required dosing frequency.

Q: Can I take Cinna if I have high blood pressure?

A: Official warnings and precautions advise caution when using Cinna in patients who have hypotension (low blood pressure) due to its vasodilatory effects. No specific contraindication is widely noted for high blood pressure.

Q: What are the non-medicinal ingredients in Cinna?

A: Official product characteristics documents list the excipients (inactive ingredients) of the medicine. These typically include substances such as Lactose Monohydrate, Maize starch, Croscarmellose sodium, and Magnesium Stearate.

How should Cinna be stored and disposed of?

How to Store and Dispose of Cinna (Cinnarizine Tablets)

Official labeling defines specific conditions to maintain the stability of Cinna (Cinnarizine). The tablets must be stored at a temperature not exceeding 30°C and should be protected from light and moisture. This medication does not require refrigeration or freezing.

For safety, Cinna must be kept out of the sight and reach of children and should not be used past its expiry date. Disposal of unused or expired product must follow regulatory procedures: Do not throw away medicines via wastewater or household waste. Consult a pharmacist for guidance on discarding the product in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cinna found in:

A-Z Index: